Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

Phase 2 Withdrawn Suzhou Zelgen Biopharmaceuticals Co.,Ltd

RandomizedParallel-groupDouble-blindTreatment

Summary

This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.

Timeline

Start: 2022-09
Primary completion: 2024-04-23
Completion: 2024-04-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Jaktinib	Unknown	75 mg	Oral
Subject	Jaktinib	Unknown	100 mg	Oral

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

Summary

Timeline

Drugs

Indications